Table 1.
Clinical characteristics of controls, COVID+ patients without smell loss, and COVID+ patients with smell loss.
| Controls (36) | COVID+ w/o SL (34) | COVID+ w/ SL (23) | p value | |
|---|---|---|---|---|
| Female gender (%) | 19 (52.8) | 15 (44.1) | 16 (69.6) | 0.166 |
| Mean age ± SD (years) | 37.1 ± 9.6 | 42.5 ± 11.4 | 39.7 ± 8.6 | 0.129 |
| Median duration of symptoms in days (IQR) | N/A | 3 (3) | 4 (4) | 0.56 |
| Ageusia (%) | N/A | 0 (0%) | 4 (17.4) | 0.02 |
| Nasal congestion (%) | N/A | 18 (52.9) | 13 (56.5) | 0.79 |
| Past respiratory diseases (%) | N/A | 3 (8.8) | 2 (8.7) | 0.98 |
| Median Q-SIT (IQR) | 3 (1) | 2 (2) | 0 (1) | <0.001 |
| Anosmia or severe microsmia (%) | 4 (11.1) | 11 (32.4) | 20 (87) | <0.001 |
COVID+ w/o SL: COVID+ patients with reported smell loss; COVID+ w/ SL: COVID+ patients without smell loss; SD: standard deviation; IQR: interquartile range.